iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/15148332
Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 May 17;199(10):1301-4.
doi: 10.1084/jem.20040730.

Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target

Christian Münz  1
Affiliations
Review

Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target

Christian Münz. J Exp Med. .

Abstract

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)--the one EBV antigen that is expressed in all EBV-associated malignancies--has long been thought to go undetected by the cell-mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV-related cancers.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Suggested antigen processing pathways of EBNA1. (A) Defective ribosomal products (DRiPs) of EBNA1 are degraded by the proteasome for MHC class I presentation (endogenous MHC class I antigen processing). (B) Full-length EBNA1 is not degraded by the proteasome and might be the source of MHC class II ligands (endogenous MHC class II antigen processing). (C) EBNA1 released by dying EBV-transformed B cells is taken up by APCs and presented for CD4+ and CD8+ T cell priming (exogenous MHC class I and II antigen processing).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell. 77:791–793. - PubMed
    1. Babcock, G.J., L.L. Decker, M. Volk, and D.A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity. 9:395–404. - PubMed
    1. Kieff, E., and A. Rickinson. 2001. Epstein-Barr Virus and its replication. Fields Virology. D.M. Knipe and P.M. Howley, editors. Lippincott-Raven, Philadelphia, PA. 2511–2573.
    1. Rickinson, A.B., and E. Kieff. 2001. Epstein-Barr Virus. Fields Virology. P.M. Knipe and P.M. Howley, editors. Lippincott-Raven, Philadelphia, PA. 2575–2627.
    1. Humme, S., G. Reisbach, R. Feederle, H.J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA. 100:10989–10994. - PMC - PubMed

Publication types

MeSH terms

Substances